Current management of symptomatic atrial fibrillation

Drugs

Volumn 61, Issue 10, 2001, Pages 1425-1437

  Channer, K S ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DILTIAZEM; DOFETILIDE; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; CARDIOVERSION; HEART ATRIUM FIBRILLATION; HEART SURGERY; HUMAN; REVIEW; THROMBOEMBOLISM;

EID: 0034859768     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161100-00006     Document Type: Review

References (72)

1. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: Population based estimates
2. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study
3. Atrial fibrillation: Current knowledge and recommendations for management
4. The contribution of atrial systole to mitral diastolic blood flow increases during exercise in humans
5. Atrial systole: Its role in normal and diseased hearts
6. Arythmie auriculaire d'origine vagale ou catecholergique: Effets compares due traitement beta-bloquant et phenomene d'echappement
7. Atrial fibrillation in healthy non-alcoholic people after an alcoholic binge
8. The role of pacemaker therapy in the prevention of atrial fibrillation
9. Prevention and treatment of supraventricular tachycardia shortly after coronary bypass grafting: A randomised open trial
10. The use of atenolol in the prevention of supraventricular arrhythmias following coronary artery surgery
11. Efficacy and safety of low and high dose sotalol versus propanolol in the prevention of supraventricular tachyarrhythmias early after coronary bypass surgery
12. Concentration-dependent pharmacologic properties of sotalol
13. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting
14. Comparison of Sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery
15. Oral d, 1 sotalol reduces the incidence of post-operative atrial fibrillation in coronary artery bypass surgery patients: A randomised double-blind placebo controlled study
16. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: The ARCH trial
17. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery
18. Multi-centre comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias
19. Maintenance of Sinus rhythm with oral d, 1, Sotalol therapy in patients With Sympathetic atrial fibrillation/atrial flutter
20. The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propanalol or propafenone
21. An open label, randomised crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation
22. Propafenone and sotalol: Long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study
23. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: A nine month follow-up of more than 500 patients
24. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter
25. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: A randomised placebo-controlled crossover trial in patients tolerating oral therapy
26. A randomised placebo controlled trial in the prevention Of paroxysmal supraventricular tachycardia and atrial fibrillation
27. Antiarrhythmic effects of azimilide in atrial fibrillation: Efficacy and dose response
28. Amiodarone to prevent recurrence of atrial fibrillation
29. Newer developments in the management of atrial fibrillation
30. Preliminary report: Effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction
31. A low incidence of proarrhythmia using low dose amiodarone
32. Oral dofetilide for conversion of atrial fibrillation/flutter to sinus rhythm: Time to cardioversion and duration of hospital
33. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins
34. Evaluation of a protocol to select patients of all ages for cardioversion from atrial fibrillation
35. Transthoracic cardioversion of atrial fibrillation: Comparison of rectilinear biphasic versus damped sine wave monophasic shocks
36. Limited internal shocks for atrial fibrillation refractory to external cardioversion
37. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter
38. Low dose amiodarone for maintenance of Sinus rhythm after cardioversion of atrial fibrillation or flutter
39. Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct current cardioversion
40. Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm
41. Cardioversion of atrial fibrillation of recent onset with flecainide
42. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation
43. Intravenous propafenone: Efficacy and safety in the conversion of sinus rhythm of recent onset atrial fibrillation - A single-blind placebo controlled study
44. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: Results of a randomised, controlled study
45. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery
46. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours
47. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation
48. The AFFIRM trial: Main trial and substudies - What can we expect
49. Rhythm or rate control in atrial fibrillation - Pharmacological intervention in Atrial Fibrillation (PIAP): A randomised trial
50. Towards improved control of atrial fibrillation
51. B-adrenoceptor blockers in atrial fibrillation: The importance of partial against activity
52. Xamoterot improves the control of chronic atrial fibrillation in elderly patients
53. The drug treatment of atrial fibrillation
54. What is meant by a 'controlled' ventricular rate in atrial fibrillation?
55. Radio frequency catheter modification of atrio-ventricular rate during atrial fibrillation
56. Atrial fibrillation: A major contributor to stroke in the elderly
57. Anti-thrombotic treatment for atrial fibrillation
58. Long term management of atrial fibrillation
59. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
60. Stroke prevention in atrial fibrillation study: Final results
61. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Study
62. Ventricular dysfunction and the risk of stroke after myocardial infarction
63. Independent prognostic value of supraventricular arrhythmias on 24 hour ambulatory monitoring following myocardial infarction
64. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era
65. Twenty-four hour ambulatory electrocardiography in elderly subjects: Prevalence of various arrhythmias and prognostic implications (report from the Bronx Longitudinal Aging Study)
66. Long term prognostic significance of ambulatory electrocardiographic findings in apparently healthy subjects >60 years of age
67. Correlation of atrial fibrillation, paroxysmal supraventricular tachycardia and sinus rhythm with incidences of new coronary events in 1359 patients mean age 81 years with heart disease
68. Clinical significance of supraventricular arrhythmias after acute myocardial infarction
69. Dofetilide in patients with congestive cardiac failure and left ventricular dysfunction
70. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study
71. Stroke severity in atrial fibrillation. The Framingham Study